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ABSTRACT : Carcinoembryonic antigen (CEA) in serum and fresh cancer tissue 
taken at surgery was measured and analyzed in terms of the disease stage. The CEA 
level in serum (s-CEA ) has become higher with advance in the disease stage. 
However, in stage V it was lowered as well as CEA level in cancer mass (ca-CEA). 
     It is suggested that S-CEA is influenced by cancer invasion into the vessel wall, 
tumor necrosis and/or degeneration which ca-CEA may well be migrated from the 
tumor cells.
       .INTRODUCTION 
 The measurement of carcinoembryonic anti-
gen (CEA) was of use to detect colon cancer 
and its recurrence in follow-up study. 
 Recently it was defined that serum CEA lev-
els were not specific to the patients with colon 
cancer and these were increased colon cancer as 
well as breast and gastric one. 
 In the present study, the clinical significance 
of CEA in patients with colon cancer was eval-
uated as compared between CEA in serum and 
tissues including cancer mass. 
   MATERIAL AND METHOD 
 Fifty-nine cases of colon cancer treated in 
our clinics were eligible in this study, 13 of
whom were advanced cases with peritoneal 
dissemination and hepatic metastasis. 
 CEA in serum (S-CEA) was measured by ra-
dioimmunoassay according to Sandwitch meth-
od using Dinabot-RIA kit, a normal values be-
ing less than 2.5 ng/ml. The fresh cancer mass 
CEA (ca-CEA) was measured from the primary 
tumor mass. These tissues as large as 0.5 to 1g 
were cut into pieces in 3-5 ml cold normal sa-
line per gram of tissue and homogenized at 4°C 
in phosphate buffer saline of pH 7.2-7.4 with 
ultrafurrox homogenizer (HITACHI 20PR-52D). 
After centrifugation at 1600g for 20 min, the 
supernatant was tested by the microimmunoas-
say method. The CEA content of tissue was 
calculated by ng/tissue weight (g) using the 
same way as that in serum.
Fig. 1. Relationship between S -CEA level and 
      tumor location, showing that S -CEA 
      levels are not specific to the tumor loca-
      tions. 
          RESULT 
 S-CEA levels were compared in association 
with tumor locations as shown in Fig. 1. 
 According to the tumor location, S-CEA lev-
els were compared as shown in Fig. 1. There 
was no characteristics of the tumor location 
among the right colon, left colon and rectum. 
 In view of the histologic stages, S-CEA was 
increased with advances in the disease stage, in 
particular it was pronounced in Stage V. On 
the contrary, it was somewhat lowered in Stage 
I and II as indicated in Fig. 2. However, in this 
study ca-CEA values in cancer mass was mea-
sured and compared with those in serum. 
The results were shown in Fig. 3. According to 
an increase in S-CEA values, ca-CEA levels were 
raised. The ca-CEA values were significantly 
higher than S-CEA one. 
  However, the S-CEA values of more than 10 
ng/ml were not necessarily proportional to ca-
CEA. The values of more than 10 ng/ml in ca-
CEA were lowered rather than those in S-CEA. 
In advanced cases with peritoneal dissemination 
and hepatic metastasis, both of CEA levels did
Fig. 2. Relationship between S-CEA levels and 
      histologic stages, indicating that S -CEA
      is increased with advancing histologic 
      stages.
Fig. 3. Relationship between CEA levels in serum 
      and cancer mass indicating that in advan-
      cing stage both are reduced.
Fig. 4. Relationship between S-CEA and ca-CEA, 
       showing no correlation with advances in 
      stages. 
not necessarily remain high. 
 In view of the histologic stage, ca-CEA level 
did not proportionally varied as shown in Fig. 
4 and in Stage V, it tended to be reduced, in 
particular, those of more than 2.5 ng /ml in 
serum changed with a wide range. 
        DISCUSSION 
 CEA was first described by GoLDa as an anti-
gen associated with carcinoma of the digestive 
tract. 
 It is well known that S-CEA level is higher in 
colon cancer patients than in normal subject. 
The S-CEA levels in patients with colon cancer 
are ranging from 35.4 ng/g to 69.9 ng/g.2) It 
is recognized that when recurrence takes place, 
the CEA values reach 68.1-97.3 ng/g.2) 
  On the contrary, a resection of carcinoma 
contributes to lowering S-CEA.1) Therefore, the 
measurement of S-CEA is of help to detect co-
lon cancer as well as appearance of its recur-
rence in follow-up study. It is not clear how 
CEA is moving from the tumor mass in which 
it is produced to the blood stream. It is assum-
ed that complex factors such as degradation of 
CEA3) and necrosis of the tumor mass`s ) may 
be contributing. It is accepted that CEA is 
drained into the gut lumen of the colon and it 
is possible to understand that S-CEA level be-
comes elevated if cancer invades the adjacent 
vessel walls. 
 In this present study, there was a tendency 
toward increasing S-CEA with advancing dis-
ease stages of colon cancer. Of interest, how-
ever, is the fact that a rise of S-CEA becomes 
depressed according to advances in colon cancer. 
It may be in part attributed to tumor necrosis 3) 
and/or CEA degeneration 4 ) by rapid growth 
of the tumor mass. It is concluded that S-CEA 
level is elevated by colon cancer and with ad-
vancing disease stages. However, it was out of 
proportion to the disease stage in advanced dis-
ease, reflecting a presence of affecting factors. 
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